World failed to achieve 2020 mental health target: WHO

New Delhi: The world missed most of the 2020 mental health targets, and has failed to provide people with the mental health services they need, at a time when the Covid-19 pandemic is highlighting a growing need for mental health support, according to a World Health Organisation (WHO) report released on Friday. The Mental Health Atlas report, released ahead of the World Mental Health Day on October 10, includes data from 171 countries. It showed that despite increase in attention given to mental health in recent years, it is yet to result in a scale-up of quality mental services that is aligned with needs.

In 2020, just 51 per cent of WHO’s 194 member states reported that their mental health policy or plan was in line with international and regional human rights instruments, way short of the 80 per cent target. Only 52 per cent of countries met the target relating to mental health promotion and prevention programmes, yet well below the 80 per cent target.

Reduction in the rate of suicide by 10 per cent, was the only target met, but even then, only 35 countries had a stand-alone prevention strategy, policy or plan, said the report released every three years.

“It is extremely concerning that, despite the evident and increasing need for mental health services, which has become even more acute during the Covid-19 pandemic, good intentions are not being met with investment,” WHO Director General, Dr Tedros Adhanom Ghebreyesus, said in a statement.

“We must heed and act on this wake-up call and dramatically accelerate the scale-up of investment in mental health, because there is no health without mental health,” he added.

  • Related Posts

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Puresta launches EVERQ, AI-powered skin-health platform

    Puresta launches EVERQ, AI-powered skin-health platform

    Stem cell therapy for autism only in approved clinical trials: Centre

    Stem cell therapy for autism only in approved clinical trials: Centre